Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

Summary Non‐endemic Burkitt lymphoma (BL) is a rare germinal centre B‐cell‐derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients tre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-05, Vol.189 (4), p.661-671
Hauptverfasser:	Jakobsen, Lasse H., Ellin, Fredrik, Smeland, Knut B., Wästerlid, Tove, Christensen, Jacob H., Jørgensen, Judit M., Josefsson, Pär L., Øvlisen, Andreas K., Holte, Harald, Blaker, Yngvild N., Grauslund, Jacob H., Bjørn, Jon, Molin, Daniel, Lagerlöf, Ingemar, Smedby, Karin E., Colvin, Katherine, Thanarajasingam, Gita, Maurer, Matthew J., Habermann, Thomas M., Song, Kevin W., Zhu, Katie Y., Gerrie, Alina S., Cheah, Chan Y., El‐Galaly, Tarec C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Burkitt lymphoma Burkitt Lymphoma - drug therapy Burkitt Lymphoma - mortality Burkitt Lymphoma - pathology Burkitt's lymphoma Clinical Medicine Female Hematologi Hematology Humans immunochemotherapy Klinisk medicin Life Sciences & Biomedicine Life span Lymphoma Male Malignancy Medical and Health Sciences Medicin och hälsovetenskap Middle Aged Myc protein Patients prognosis real-world patients Remission Retrospective Studies Science & Technology Survival Survival Analysis Treatment Outcome Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!